Response to: cytokine profile of autologous conditioned serum for treatment of osteoarthritis, in vitro effects on cartilage metabolism and intra-articular levels after injection
Groenemeyer Institute for Microtherapy, Universitaetsstrasse 142, 44799 Bochum, Germany
Arthritis Research & Therapy 2010, 12:410 doi:10.1186/ar3146
See related research by Rutgers et al., http://arthritis-research.com/content/12/3/R114 and related letter by Rutgers et al., http://arthritis-research.com/content/12/6/411Published: 17 December 2010
First paragraph (this article has no abstract)
We welcome the interest of Rutgers and colleagues  in providing additional information on the mode of action of autologous conditioned serum (ACS). Studies such as the one they published in a recent issue of Arthritis Research & Therapy are important because the Orthokine ACS treatment (Orthogen, Düsseldorf, Germany) has been shown to be safe and effective in a number of clinical studies and is used widely in Europe. Randomized controlled trials have confirmed the efficacy of this treatment in osteoarthritis of the knee and lumbar radiculopathy. Additional human studies show promise in treating muscle injury and tunnel widening after anterior cruciate ligament (ACL) reconstruction. All clinical and preclinical studies confirm an excellent risk-to-benefit ratio. We would like to offer some comments concerning the paper of Rutgers and colleagues.